AstraZeneca [NASDAQ: AZN] Inaugurate The Discovery Centre in Cambridge

AstraZeneca PLC [NASDAQ: AZN] has announced the launch of The Discovery Centre (DISC) in Cambridge, UK. DISC is an advanced R&D facility aimed at the world’s highest environmental standards and employing over 2,200 research scientists. The formal inauguration was carried out in presence of His Royal Highness The Prince of Wales.

The DISC would add to AstraZeneca’s R&D presence in more than 40 countries across the globe. It includes its other strategic research centre in Sweden and the US and development facilities in China and Japan. The Company makes an investment of more than $7bn in R&D globally each year. The Centre will further foster collaborations, develop the next generation of science leaders, and speed up AstraZeneca’s industry-leading levels of productivity.\

The Discovery Centre

In addition, the new £1bn facilities will encompass the most sophisticated robotics, high-throughput screening, and AI-driven technology. It will back AstraZeneca’s focus on specialized and precision medicines. Moreover, it will also promote the exploration and development of next-generation therapeutics, including nucleotide-based, gene-editing, and cell therapies.

AstraZeneca disclosed that its aim is to not only inaugurate a building but to also accelerate the next wave of scientific innovation. AZN’s new Discovery Centre in Cambridge improves sustainable R&D and global cooperation across its industry. It will enable the firm to sever new boundaries in the knowledge of disease biology, make life-changing medicines for patients, and power the next stage of its company’s growth.

Furthermore, the DISC will add to AstraZeneca’s R&D presence in more than 40 countries across the globe. It includes its other strategic research centres in Sweden and the US, and development facilities in China and Japan. It is situated within the Cambridge Biomedical Campus, the physical proximity of the building’s 19,000m2 laboratories to leading hospitals, the University of Cambridge, other research institutions and a number of biotech companies will advance a culture of open collaboration in its inviting open spaces.

The Company has more than 200 active partnerships in the region and more than 2,000 around the world across academia, biotech, and industry. Moreover, the structure of the building is also very unique. It has low-energy ventilation and high levels of insulation also guarantee the efficiency of the building, along with the ‘saw-tooth roof design which reduces energy use by swamping the interior with natural daylight.